Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks
1. HC Wainwright rates Ultragenyx (RARE) as a Buy with a $80 price target. 2. RARE stock down 35% year-to-date, underperforming the benchmark XBI index. 3. The Orbit trial's final results for UX143 expected to be positive. 4. Current commercial portfolio could support fair value of $35-$40/share. 5. FDA's Complete Response Letter for UX111 requires resubmission by mid-2026.